fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Jack Daniel’s & Coca-Cola Cocktail Going Global As Pre-mixed Option In 2023 – $KO $DIA $SPY $INVO

By John F. Heerdink, Jr.

As per reports, the iconic Jack Daniel’s & Coca-Cola Company (KO) cocktail will be introduced in the United States as a pre-mixed, ready-to-drink (RTD) option for the first time. This beverage is inspired by a popular bar-call cocktail and contains Jack Daniel’s Tennessee Whiskey and Coca-Cola. It was initially launched in Mexico last year and will gradually expand to other markets globally throughout 2023. The drink has an ABV of 7% in the US, and from May, a version with Coca-Cola Zero-Sugar will also be available. It will be available at retailers nationwide and will be sold at a suggested retail price of $12.99 per 4-pack.

“This launch is a milestone moment for both Coca-Cola and Jack Daniel’s – it is following what people have been doing with these two iconic brands for generations and demonstrates our commitment to innovation from the simple to the complex. We are really excited about this classic cocktail being offered in a new and exciting way through our relationship with Jack Daniel’s and their distributor system,” stated Dan White, Chief of New Revenue Streams for The Coca-Cola Company. “
 
 

Dow 30 Component, The Coca-Cola Company (KO), is the largest total beverage company in the world. It offers 500 plus brands in over 200 countries and is committed to reducing sugar in its drinks and providing new and diverse drinks to people everywhere. To learn more about The Coca-Cola Company (KO) and to continue to track its progress please visit the Vista Partners Coca-Cola Company Coverage Page.

 
 
 
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
 


DID YOU KNOW?…

 
On Monday, March 20, INVO Bioscience (NASDAQ: INVO) announced that it has signed binding agreements to acquire a materially transformative acquisition of the Wisconsin Fertility Institute. The Madison-based fertility center primarily offers conventional IVF procedures and generated approximately $5.5 million in revenue and net income of approximately $1.9 million for the trailing 12-month period ended September 30, 2022.
 
 
 
Wisconsin Fertility Institute is led by internationally renowned and well-respected fertility expert, Dr. Elizabeth Pritts, who will continue to serve as the clinic’s lead physician for a minimum period of three years from the closing of the acquisition. Dual-certified in General Obstetrics and Gynecology, as well as Reproductive Endocrinology and Infertility, Dr. Pritts completed a surgical fellowship in Advanced Gynecologic Laparoscopy and Hysteroscopy. She is also a national leader in the use of robotic surgery for gynecologic disorders. Dr. Pritts served as an assistant professor in reproductive endocrinology and infertility at the University of Wisconsin Medical School, as a clinical fellow at the University of California at San Francisco, and as an instructor at Yale University School of Medicine. She has authored more than 70 articles for scientific publications and has lectured throughout the world on reproduction and fertility.
 
 

Dr. Elizabeth Pritts, M.D., Wisconsin Fertility Institute’s Co-founder

 
 
“I’m excited to be teaming up with INVO as a unique and attractive partner to help advance us to the next phase of our practice. INVO’s commercial strategy and patient focus, along with its public-company platform and the INVOcell technology itself, offers an exciting pathway to build value and increase access to an efficient, effective, affordable, and connected experience in reproductive treatment. Our team looks forward to being an integral part of INVO’s long-term growth and success.” Dr. Elizabeth Pritts, Wisconsin Fertility Institute’s co-founder.
 
 
 
Wisconsin Fertility Institute joins INVO’s expanding list of fertility clinics, including operating clinics in Atlanta (Bloom Fertility), Birmingham (Innovative Fertility Specialists) and Monterrey, Mexico (Positib Fertility), as well as future clinics under development, such as the wholly owned INVO Center in Tampa, Florida that is currently under construction. INVO’s revolutionary medical device, the INVOcell, allows fertilization and early embryo development to occur in vivo with the woman’s body and is also available at a growing list of non-affiliated fertility centers in the United States and around the world.
 
(Read Original Story: Jack Daniel's and Coca-Cola® Ready-to-Drink Launches in the U.S. in PR NewsWire)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us